Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
David Cunningham(Royal Marsden NHS Foundation Trust), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Stephen Falk(At Bristol), Sam Rowley(MRC Clinical Trials Unit at UCL), Heike I. Grabsch(University of Leeds), Sally Stenning(Medical Research Council), Derek Alderson(University of Bristol), S M Griffin(Royal Victoria Infirmary), Jane Blazeby(Royal College of Surgeons of England), Alicia Okines(Royal Marsden NHS Foundation Trust), Wasat Mansoor(The Christie NHS Foundation Trust), Elizabeth Smyth(National Health Service), Suzanne Darby(Weston Park Cancer Centre), Laura Stevenson(University College London), Kate Sumpter(Freeman Hospital), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), T. Crosby(Velindre Cancer Centre), William Allum(Royal Marsden Hospital)
Cited by 286
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k